Cost-effectiveness of nonavalent HPV vaccination in the Netherlands

Cody Palmer,Christiaan Dolk,Ugne Sabale,Wei Wang,Kunal Saxena
DOI: https://doi.org/10.1080/14760584.2024.2322543
2024-03-03
Expert Review of Vaccines
Abstract:Background A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.
immunology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate the cost - effectiveness of a gender - neutral HPV vaccination strategy using the 9 - valent human papillomavirus vaccine (9vHPV) in the Netherlands compared to the currently used bivalent HPV vaccine (2vHPV). Specifically, the study aims to determine whether the shift from 2vHPV to 9vHPV is cost - effective by comparing the public health and economic benefits of the two vaccination strategies. In addition, the study also considers different scenarios, including a catch - up program for people aged 26 and below, to further evaluate the impact of these strategies. The study compared the effects of 2vHPV and 9vHPV vaccination strategies within a 100 - year simulation time through a validated deterministic dynamic transmission meta - population model. The results showed that, compared with 2vHPV, the 9vHPV strategy can prevent an additional 3,245 cancer cases caused by 9vHPV - related virus strains and 825 cancer deaths, 4,247 cases of recurrent respiratory papillomatosis (RRP) and 190 RRP deaths, as well as 1,009,637 cases of genital warts. The incremental cost - effectiveness ratio (ICER) is €4,975 per additional quality - adjusted life year (QALY). This result indicates that the shift from 2vHPV to 9vHPV vaccination strategy is cost - effective in the Netherlands.